Abound Wealth Management’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$196K Hold
3,506
– – 0.04% 115
2026
Q2
$193K Hold
3,506
– – 0.04% 101
2026
Q1
$116K Hold
3,506
– – 0.03% 137
2025
Q4
$105K Hold
3,506
– – 0.02% 134
2025
Q3
$127K Hold
3,506
– – 0.03% 113
2025
Q2
$126K Buy
3,506
+3,498
+43,725% +$130K 0.04% 105
2025
Q1
$316 Sell
8
-2
-20% -$67 ﹤0.01% 865
2024
Q4
$301 Hold
10
– – ﹤0.01% 894
2024
Q3
$234 Buy
+10
New +$218 ﹤0.01% 1076

Other funds holding TGTX

Abound Wealth Management's TGTX Position: Q3 2026 in Review

Abound Wealth Management held its TG Therapeutics (TGTX) position steady in Q3 2026 at 3,506 shares worth $196K. The position accounts for 0.04% of the portfolio, ranked #115.

Abound Wealth Management first reported a position in TGTX in Q3 2024 and has held it in 9 quarters since. 451 funds tracked by Wall St. Rank hold TGTX as of Q3 2026.

  • Abound Wealth Management held 3,506 shares of TG Therapeutics worth $196K as of Q3 2026.
  • Abound Wealth Management left its TG Therapeutics share count unchanged in Q3 2026.
  • TG Therapeutics made up 0.04% of Abound Wealth Management's portfolio in Q3 2026, its #115 holding.
  • Abound Wealth Management first reported a position in TG Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • 451 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2026.

Based on Abound Wealth Management's 13F filing for Q3 2026, filed 26 Oct 2026.